Fig. 2
In vivo behavior of xenogeneic BRAF-mutated and BRAF wt CRC. a Quantitative time-course analysis of mice injected with luciferase-tagged BRAFV600E (top) and BRAF wt CCSCs (middle and bottom). The progression of human CRCs was monitored from 3DPT (left) next to the end-stage disease typical of each CCSCs injected. b Histologic analysis, as expressed by H&E staining, revealing features of human serrated CRC with villiform architecture, micropapillary clusters and signet ring cells in BRAFV600E lesions (top) while marked nuclear atypia and hemorrhagic necrosis (middle and bottom) were detected in BRAF wt CRCs. c OCT-embedded lung sections (left) marked with H&E (middle) depicting pulmonary lesions (arrowhead) in mice infused with BRAFV600E CCSCs into the lateral tail-vein (n = 3 mice per groups). Widespread immunoreactivity for the human nuclei marker in BRAFV600E lesions is shown (right). Scale bars, 1000um, 100um and 50um